News – Page 861 – Endpoints News

Doing deals in a time of coronavirus: Biotech CEO Bill Haney says 'you focus on the things that make a difference'

6 years ago

Biogen flags delays on Spinraza treatments as hospitals shift focus and resources to pandemic patients

6 years ago

GSK quietly reveals just how much cash they used to buy a chunk of the Bay Area's buzziest startup

6 years ago

New data from randomized trial dent HIV drug strategy against Covid-19

6 years ago

Covid-19 roundup: Fred Hutch cuts down further on lab work, Roche joins Regeneron and Sanofi in IL-6 trials, China ...

6 years ago

A Japanese flu drug gets upbeat reviews in China for blunting the impact of Covid-19 — and that is bolstering ...

6 years ago

Bayer fires employee who was spotted breaking quarantine in China

6 years ago

Insilico inks another deal with Sino Biopharma unit; Ramaswamy's Datavant to invest in the "patient journey"

6 years ago

Sage plots comeback plan for its experimental oral antidepressant

6 years ago

Covid-19 roundup: Trump backtracks on NIH/CDC funding, Novartis launches $20M fund, FDA and ICER cancellations

6 years ago

Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief

6 years ago

TCR player Immatics combines with Perceptive’s blank check operator, scooping $252M and gaining a listing on Nasdaq

6 years ago

Covid-19 could throw final hurdle into AbbVie and Allergan’s massive merger

6 years ago

As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it?

6 years ago

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

6 years ago

Contract manufacturer: FDA has halted domestic pharma inspections

6 years ago

The big C: The dealmakers, dollars and diseases that have transformed the Chinese biopharma market

6 years ago

UK takes tougher stance to combat coronavirus, as previous approach risks hundreds of thousands of lives — study

6 years ago

Rick Klausner's Lyell partners, helps fund Eureka's work on cell therapies; Blueprint bounces higher on PhII

6 years ago

Merck touts PhIII data burnishing $500M platform — what kind of bar does it set for a chronic cough drug?

6 years ago

Safety issues force Novo Nordisk to shutter PhIII hemophilia trials

6 years ago

‘Patient zero’ in Tennessee talks about fear, anxiety, hysteria and countless acts of kindness as the Biogen ...

6 years ago

Flagship’s Sigilon grabs $80M to bring Robert Langer cell therapy tech into the clinic

6 years ago

Covid-19 roundup — Regeneron zooms in on cocktail; BioNTech shares skyrocket on quick Pfizer alliance

6 years ago

First page Previous page 858 859 860861862 863 864 Next page Last page